Tricuspid regurgitation (TR) is a common cardiac valve disease for which conventional medical therapy offers limited benefits and surgical intervention carries significant risks. With advancements in transcatheter tricuspid valve intervention (TTVI) techniques, it has emerged as an important treatment option for patients with severe TR who are at high surgical risk. Based on Chinese Expert Consensus on Transcatheter Tricuspid Valve Intervention Therapy, this article provides an in-depth discussion on key aspects including TR pathological classification and prognosis, indication criteria, treatment strategies, selection of TTVI devices, study endpoints, and multidisciplinary team building. The aim is to elucidate the content of the consensus, enhance readers’ systematic understanding of TTVI, and promote the safe and standardized adoption of this technology in China.
